Baik, Christina http://orcid.org/0000-0003-4503-6712
Cheng, Michael L. http://orcid.org/0000-0002-7409-288X
Dietrich, Martin http://orcid.org/0009-0001-9989-3536
Gray, Jhanelle E. http://orcid.org/0000-0003-1304-7062
Karim, Nagla A. http://orcid.org/0000-0002-8913-793X
Funding for this research was provided by:
Pfizer
Article History
Received: 5 January 2024
Accepted: 8 March 2024
First Online: 2 May 2024
Change Date: 4 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-024-02907-9
Declarations
:
: Christina Baik reports grant funding from AstraZeneca, Rain Oncology, Nuvalent, Blueprint, TurningPoint, Bristol Myers Squibb, Lilly, Jansen, Daiichi Sankyo, Spectrum, Pfizer, Loxo, Boehringer Ingelheim, Genentech/Roche, and the National Institutes of Health/National Cancer Institute, as well as consulting fees from Daiichi Sankyo, Boehringer Ingelheim, Novartis, Jansen, Regeneron, Silverback, Pfizer, AstraZeneca, Guardant, TurningPoint, Takeda, and Genentech. Michael Cheng reports honoraria from the Lynx Group, WebMD, and Potomac Center for Medical Education; has had a consulting or advisory role with AstraZeneca, Inivata, Boehringer Ingelheim, Cephied, Mirati, Janssen, Pfizer, and Noetik; research funding from Palleon Pharmaceuticals; and travel, accommodations, and expenses from Daiichi Sankyo, AstraZeneca, and Genzyme. Martin Dietrich reports a speaking or service role with Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Caris Life Sciences, Daiichi Sankyo, Eli Lilly & Co, EMD Serono, Epizyme, Foundation Medicine, G1 Therapeutics, Genentech, Gilead Pharmaceuticals, Janssen Pharmaceuticals, Mirati Therapeutics, Myriad, Novartis, Pfizer, Puma, Regeneron, Sanofi Genzyme, Stemline Oncology, and Takeda; and a consulting role with Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Caris Life Sciences, Daiichi Sankyo, Eli Lilly & Co, EMD Serono, Epizyme, Foundation Medicine, G1 Therapeutics, Genentech, Gilead Pharmaceuticals, Janssen Pharmaceuticals, Mirati Therapeutics, Myriad, Novartis, Pfizer, Puma, Regeneron, Sanofi Genzyme, Stemline Oncology, and Takeda. Jhanelle Gray reports a consulting role with Amgen, Gilead, and Grid; grants and personal fees from AstraZeneca, Bristol Myers Squibb, Genentech, Merck & Co, Inc, and Novartis; personal fees from AbbVie, Axiom HC Strategies, Blueprint Medicines, Celgene, Daiichi Sankyo, Inc, EMD Serono—Merck KGaA, Inivata, Janssen Scientific, Jazz Pharmaceuticals, Loxo Oncology Inc, OncoCyte Biotechnology, Sanofi Pharmaceuticals, and Takeda Pharmaceuticals; grants from Boehringer Ingelheim, G1 Therapeutics, Ludwig Institute of Cancer Research, and Pfizer; and research funding from Gilead and Pfizer. Nagla Karim reports research funding from Pfizer, Bristol Myers Squibb, Exelixis, and Genentech; speaker’s bureau from Regeneron, AstraZeneca, and Sanofi; and advisory board role with Jazz, Merck, Pfizer, Amgen, and G1 Therapeutics.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.